• Bio-Path Holdings posted a GAAP net loss of USD 2.91 million, narrowing from USD 7.45 million a year earlier.
• Operating loss improved to USD 1.23 million from USD 7.8 million, while net loss per share narrowed to USD 0.15 from USD 0.97.
• Research and development expense fell to USD 916,000 from USD 6.03 million due to pausing BP1001 and BP1001-A clinical trials.
• General and administrative costs dropped to USD 318,000 from USD 1.78 million on lower overhead following 2025 workforce reductions.
• Board launched an AI-driven digital asset treasury, opened a Coinbase business account, and said it intends to allocate up to 50% of raised capital to crypto.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Path Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001663577-26-000256), on August 20, 2026, and is solely responsible for the information contained therein.